Geron Corporation, a commercial-stage biopharmaceutical company, will be presenting at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will feature presentations on RYTELO® (imetelstat), highlighting its efficacy and safety across a range of patients with lower-risk myelodysplastic syndromes (LR-MDS) and showcasing progress with the IMpactMF and IMproveMF trials in myelofibrosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.